The evolution of thalidomide and its IMiD derivatives as anticancer agents (Q44824886)

6 December 2017

1 reference

title

The evolution of thalidomide and its IMiD derivatives as anticancer agents (English)

1 reference

6 December 2017

0 references

J Blake Bartlett

1

1 reference

6 December 2017

Keith Dredge

series ordinal

2

1 reference

6 December 2017

Angus G Dalgleish

series ordinal

3

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

6 December 2017

published in

Nature Reviews Cancer

1 reference

6 December 2017

volume

4

1 reference

6 December 2017

issue

4

1 reference

6 December 2017

page(s)

314-322

1 reference

THALIDOMIDE AND CONGENITAL ABNORMALITIES

6 December 2017

cites work

1 reference

Neuropathy after intake of thalidomide (distaval)

31 March 2020

1 reference

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

31 March 2020

1 reference

Thalidomide as an emerging immunotherapeutic agent

31 March 2020

1 reference

Thalidomide--a revival story

31 March 2020

1 reference

Thalidomide on the comeback trail

31 March 2020

1 reference

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

31 March 2020

1 reference

Thalidomide a promising new treatment for rheumatoid arthritis

31 March 2020

1 reference

Treatment of Behçet's disease with thalidomide

31 March 2020

1 reference

Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation

31 March 2020

1 reference

Thalidomide treatment for chronic graft-versus-host disease

31 March 2020

1 reference

Thalidomide for the treatment of chronic graft-versus-host disease

31 March 2020

1 reference

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

31 March 2020

1 reference

Effect of thalidomide on chemokine production by human microglia

31 March 2020

1 reference

Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells

31 March 2020

1 reference

Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

31 March 2020

1 reference

Thalidomide in Crohn's disease

31 March 2020

1 reference

Thalidomide is an inhibitor of angiogenesis

31 March 2020

1 reference

A developmental model for thalidomide defects.

31 March 2020

1 reference

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

31 March 2020

1 reference

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

31 March 2020

1 reference

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

31 March 2020

1 reference

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma

31 March 2020

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

31 March 2020

1 reference

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.

31 March 2020

1 reference

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

31 March 2020

1 reference

Thalidomide and Its Derivatives: New Promise for Multiple Myeloma

31 March 2020

1 reference

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

31 March 2020

1 reference

The treatment of advanced renal cell cancer with high-dose oral thalidomide

31 March 2020

1 reference

Current status of thalidomide and its role in the treatment of metastatic prostate cancer

31 March 2020

1 reference

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

31 March 2020

1 reference

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

31 March 2020

1 reference

Thalidomide: a new anticancer drug?

31 March 2020

1 reference

Thalidomide as an anti-cancer agent.

31 March 2020

1 reference

Immunotherapeutic and antitumour potential of thalidomide analogues

31 March 2020

1 reference

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

31 March 2020

1 reference

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

31 March 2020

1 reference

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

31 March 2020

1 reference

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

31 March 2020

1 reference

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

31 March 2020

1 reference

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

31 March 2020

1 reference

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

31 March 2020

1 reference

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

31 March 2020

1 reference

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

31 March 2020

1 reference

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

31 March 2020

1 reference

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

31 March 2020

1 reference

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

31 March 2020

1 reference

Taming TNF: strategies to restrain this proinflammatory cytokine

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1323

1 reference

6 December 2017

1 reference